Moderna announces first participants dosed in phase 3 study of seasonal influenza vaccine candidate (mrna-1010)

Mrna-1010 is moderna's first seasonal influenza vaccine candidate to enter a phase 3 trial mrna-1010 is one of several influenza vaccine candidates being developed in moderna's respiratory portfolio moderna now has four programs in phase 3 studies: omicron-containing bivalent covid booster, influenza, rsv, cmv cambridge, ma / accesswire / june 7, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced the first participants have been dosed in a phase 3 study of the company's seasonal influenza vaccine candidate (mrna-1010). the trial is expected to enroll approximately 6,000 adults in southern hemisphere countries.
MRNA Ratings Summary
MRNA Quant Ranking